EX-99.1 2 d110914dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G, dated February 5, 2021 (the “Schedule 13G”), with respect to the common stock, par value $0.01 per share, of Beam Therapeutics Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an exhibit to the Schedule 13G and each such amendment.

Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 5th day of February, 2021.

 

Dated: February 5, 2021   TEMASEK HOLDINGS (PRIVATE) LIMITED
    By:  

/s/ Andrew Ang Lye Whatt

        Name   :   Andrew Ang Lye Whatt
        Title   :   Authorized Signatory
Dated: February 5, 2021   FULLERTON MANAGEMENT PTE LTD
    By:  

/s/ Gregory Tan

        Name   :   Gregory Tan
        Title   :   Director
Dated: February 5, 2021   TEMASEK LIFE SCIENCES PRIVATE LIMITED
    By:  

/s/ Lim Siew Lee Sherlyn

        Name   :   Lim Siew Lee Sherlyn
        Title   :   Director
Dated: February 5, 2021   TLS BETA PTE. LTD.
    By:  

/s/ Zahedah Abdul Rashid

        Name   :   Zahedah Abdul Rashid
        Title   :   Director